Targeting the Checkpoint Receptor TIGIT via CRISPR/Cas9 Genome Editing to Enhance NK Cell Anti-Tumor Activity |
Research Institute at Nationwide Children's Hospital |
Northwestern Mutual Foundation |
Synthetic Gene Expression Regulatory Switches (SynGERS) for Improved CAR T Cell Function in Pediatric Solid Tumors |
Baylor College of Medicine |
Northwestern Mutual Foundation |
Arginine Depletion with DFMO in High-Risk Neuroblastoma |
Children’s Hospital of Philadelphia |
Northwestern Mutual Foundation |
A Novel Adjunctive LAT-Activating CART (ALA-CART) Cell Platform for the Treatment of Acute Leukemia |
University of Colorado Denver_ Anschutz Medical Campus |
Northwestern Mutual Foundation |
Creating an Infrastructure for Collaborative Clinical Research and Publication of Consensus Guidelines for RUNX1 Familial Platelet Disorder |
The Cleveland Clinic Foundation |
The RUNX1 Research Program |
Mutagenesis and disease progression in RUNX1 mutant blood stem cells is caused by inflammation-induced hyperactive signaling and supraphysiological mitochondrial ROS |
St. Jude Children’s Research Hospital |
The RUNX1 Research Program |
Investigating the Role of the MYCN Oncogene in Regulating Chemokine Expression in Neuroblastoma |
Children’s Hospital of Philadelphia |
Northwestern Mutual Foundation |
Structural rearrangement signatures as novel biomarkers for homologous recombination deficiency in cancer
|
Dana-Farber Cancer Institute |
Northwestern Mutual Foundation |
FGFR1 alterations in pediatric gliomas
|
Dana-Farber Cancer Institute |
Northwestern Mutual Foundation |
Synthetic Gene Expression Regulatory Switch engineered CAR T cells for children with cancer
|
Baylor College of Medicine |
Northwestern Mutual Foundation |